How FDA Inspections Work: Facilities and Manufacturers

FDA inspections are the primary mechanism through which the agency verifies that manufacturers, processors, repackers, and other regulated entities are operating in compliance with federal law. Covering domestic and foreign facilities that produce drugs, biologics, medical devices, food, cosmetics, and tobacco products, the inspection system is grounded in authority granted by the Federal Food, Drug, and Cosmetic Act (FD&C Act). Understanding how inspections are initiated, conducted, and resolved is essential for any facility subject to FDA jurisdiction, as outcomes can trigger enforcement actions, import alerts, or mandatory recalls.

Definition and scope

An FDA inspection is an official examination of a regulated facility's records, processes, equipment, personnel practices, and physical premises to assess compliance with applicable statutes and regulations. The legal authority for these inspections is established primarily under 21 U.S.C. § 374, which grants FDA investigators the right to enter and inspect factories, warehouses, establishments, and vehicles used for manufacturing, processing, packing, or holding food, drugs, devices, and cosmetics.

The scope of an inspection depends on the product category and the facility type. A pharmaceutical manufacturer is evaluated against Current Good Manufacturing Practice (cGMP) regulations codified at 21 C.F.R. Parts 210 and 211, while a medical device manufacturer is held to Quality System Regulation standards under 21 C.F.R. Part 820. Food facilities are inspected under standards shaped by the Food Safety Modernization Act (FSMA), which expanded both the frequency and risk-based prioritization of food facility inspections.

Domestic facilities registered with FDA number in the tens of thousands, and the agency also inspects foreign facilities that export regulated products to the United States — a function described in FDA's import regulations framework.

How it works

FDA inspections follow a structured operational sequence:

1. Pre-inspection planning. FDA's Office of Regulatory Affairs (ORA) selects facilities for inspection based on risk-ranking algorithms, complaint histories, time elapsed since last inspection, and statutory mandates. FSMA, for example, requires that high-risk food facilities be inspected at least once every 3 years and non-high-risk facilities at least once every 5 years (21 U.S.C. § 350g note, FSMA § 201).

2. Entry and credentials. One or more FDA investigators arrive at the facility and present FDA Form 482 (Notice of Inspection), which formally initiates the inspection. Facilities generally may not refuse entry without risking enforcement consequences, though certain protections apply for trade secret documentation.

3. Records review and physical examination. Investigators examine batch records, standard operating procedures, cleaning and maintenance logs, complaint files, and laboratory test results. They also conduct physical walk-throughs to assess equipment condition, environmental controls, personnel hygiene, and contamination controls.

4. Collection of samples. Investigators may collect product samples for independent laboratory testing. These samples can later form the basis of adulteration or misbranding findings.

5. Issuance of FDA Form 483. At the close of the inspection, investigators present a Form 483 listing all observed conditions that, in the investigator's judgment, may constitute violations of the FD&C Act or applicable regulations. This document is not a final agency determination — it is an itemized list of inspectional observations.

6. Establishment Inspection Report (EIR). After returning to their district office, investigators prepare an EIR summarizing all findings. The EIR informs the agency's final classification decision.

7. Official Action and classification. FDA assigns one of three classifications to each inspection: No Action Indicated (NAI), Voluntary Action Indicated (VAI), or Official Action Indicated (OAI). OAI classifications can trigger Warning Letters, injunctions, consent decrees, or seizure actions, which are described in greater detail under FDA enforcement actions and recalls.

Common scenarios

Drug and pharmaceutical manufacturing. A cGMP inspection at a drug facility focuses on batch record accuracy, equipment qualification, water system validation, and personnel training. A single sterility failure or an unexplained out-of-specification result can generate multiple Form 483 observations. Repeat OAI classifications at the same facility commonly lead to Warning Letters published on FDA's website.

Medical device facilities. Device inspections assess design controls, corrective and preventive action (CAPA) systems, and complaint handling per 21 C.F.R. Part 820. A facility seeking 510(k) clearance or Premarket Approval (PMA) may face a pre-approval inspection (PAI) before FDA completes its review — a distinct inspection type triggered by the submission rather than a routine scheduling cycle.

Food manufacturing. Post-FSMA food inspections evaluate Hazard Analysis and Risk-Based Preventive Controls (HARPC) plans, supplier verification programs, and environmental monitoring for pathogens such as Listeria monocytogenes. Findings here may connect directly to the food recalls and outbreaks process if contamination is confirmed.

Foreign facility inspections. FDA conducts inspections at overseas manufacturing sites, particularly in India and China, which are major sources of active pharmaceutical ingredients (APIs). Foreign inspections follow the same Form 482/483/EIR sequence, though logistical coordination with foreign regulatory authorities may occur in parallel.

Decision boundaries

The NAI/VAI/OAI classification framework represents the primary decision boundary that determines whether an inspection triggers formal regulatory consequences.

A facility's response to a Form 483 — submitted within 15 business days by convention — can influence whether a VAI classification escalates to OAI. A detailed, credible corrective action plan with documented implementation timelines reduces the probability of escalation. Conversely, incomplete responses or patterns of repeated observations across multiple inspection cycles increase the likelihood of formal enforcement.

For context on how Good Manufacturing Practices standards underpin most inspection criteria, or to understand the broader regulatory landscape covered across this reference site, those resources provide additional structural detail.